NHS cancer patients to get pioneering genetic test to find best treatments

Description

"Thousands of NHS cancer patients who have exhausted other treatment options are being offered liquid biopsy blood tests to match them to personalised medicines".

Marking the launch of the TARGET National study, led by Dr Matthew Krebs from the University of Mancheser and The Christie NHS Foundation Trust, liquid biopsy testing (ctDNA) will be made available across the Experimental Cancer Medicine Network (18 adult centres) to offer genetic testing to cancer patients being considered for early phase clinical trials. 

The study broadens access to genetic testing from ctDNA across the UK and aims to match patients to experimental medicines available across the network. 

A virtual national Molecular Tumour Board has also been launched, meeting twice a month, to harness expertise from across the Country in intepreting genetic results and identifying suitable trials. 

Funded by The Christie Charity, The SIr Bobby Robson Foundation and F.Hoffmann-La Roche Ltd